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Abstract
Recent work has revealed the causative links between deregulation of microRNAs (miRNAs) and cancer de-
velopment. In hepatocellular carcinoma (HCC), aberrant expression of miRNAs has been observed, but the
molecular mechanisms that contribute to such changes remains to be elucidated. Here, we reported the analysis
of miRNA expression in 94 pairs of tumor and adjacent nontumor tissues from HBV-associated HCC in Chinese
patients. We found miRNAs were aberrantly expressed in HCC tissues. To investigate the cause of such de-
regulation, we detected changes in DNA copy number by measuring locus-specific hybridization intensity, and
found changes in expression of several miRNAs are correlated with genomic amplification or deletion. For
example, the genomic regions of miR-30d and miR-151 were amplified in*50% of HCC tumor tissues, and the
expressions of these miRNAs are significantly correlated with DNA copy number. We also employed cDNA
microarray data, and provide evidence that key regulators of the miRNA biosynthetic pathway, including
DROSHA, DGCR8, AGO1, and AGO2, are frequently overexpressed in HCC. This study provides molecular
clues that may contribute to the global changes of miRNA expression in HCC.
Introduction
Hepatocellular carcinoma (HCC) is a lethal malig-nancy with no effective interventions, and causes ap-
proximate 600,000 deaths each year (Parkin et al., 2005). The
difficult clinical situation is due to lack of early diagnosis,
limited options for treatments, and the heterogeneous nature
of the disease. Different mechanisms contribute to the het-
erogeneity, including chromosomal abnormality, epigenetic
regulation, and copy number variation. Recently, in addition
to these mechanisms, microRNA (miRNA) deregulation has
emerged as a new mechanism affecting HCC biology.
miRNAs are about 22-nucleotide long, noncoding RNAs that
play an important role in regulating gene expression at post-
transcriptional level (Lagos-Quintana et al., 2002). Growing
evidence showed that they are involved in diverse cellular
processes, including apoptosis, cell proliferation, stress resis-
tance, and cell differentiation (Esquela-Kerscher and Slack,
2006). Given the wide impact of miRNAs, it is not surprising
that a number of them are implicated in cancer. miRNAs are
expressed abnormally in various types of cancer, including
HCC (Budhu et al., 2008; Foekens et al., 2008; Yanaihara et al.,
2006). The underlyingmechanism bywhich miRNA expression
is deregulated inHCChas been unclear so far, although in some
cancers it could be resulted in part from genomic amplification
or deletion, mutation, and epigenetic silencing (Garzon et al.,
2009). In this context, we employ the sensitive and accurate real-
time quantitative-PCR (qPCR) detection method to profile 220
miRNAs in a cohort of 94 pairs of tumor and adjacent nontumor
HCC tissues. We explore the mechanisms that contribute to the
aberrant expression of miRNAs and performed integrated
analysis of single nucleotide polymorphism (SNP) array data
and mRNA expression data of enzymes involved in miRNA
biogenesis.We found that in some instances,miRNAexpression
is correlatedwith DNA copy number, and enzymes involved in
miRNA biogenesis are frequently deregulated in HCC.
Materials and Methods
Clinical samples
Human HCC samples were collected from patients who
had undergone hepatectomy for curative treatment of HCC at
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Queen Mary Hospital, Pokfulam, Hong Kong, between 1990
and 2007. Resected tumor and adjacent nontumor liver tissues
were obtained as described (Hao et al., 2009). Informed con-
sents were obtained from patients regarding the use of the
liver specimens for research. Demographic and clinicopatho-
logic features are as described (Burchard et al., 2010).
RNA extraction
The milled human liver tissue samples were homogenized
in cryopreservation tubeswith a vortexmixer after addition of
TRIzol (Invitrogen, Carlsbad, CA, USA). The total RNA was
further purified using the Promega SV-96 total RNA kit
(Promega Corp., Madison, WI, USA), and then assayed by
Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA) for quality. The yield was assayed by Ribogreen metrics
(Invitrogen Corp.).
miRNA and cDNA profiling
miRNA profiling was performed using custom made
quantitative PCR assays as described (Raymond et al., 2005).
cDNA profiling was performed using custom Affymetrix ar-
ray, RM-HU01Aa520485 RSTA Custom Affymetrix 1.0. Hy-
bridization, labeling and scanning of microarrays were
performed according to themanufacturer’s recommendations
(Affymetrix Inc., Santa Clara, CA, USA) (Burchard et al.,
2010).
Copy number variation (CNV) analysis
CNV was measured using the Illumina platform that con-
tains a 650K array, and the results are expressed as the logR
ratio (that is, the intensity ratio of the studied sample to a
number of reference samples). The genomic locations of each
differentially expressed miRNA and the single-nucleotide
polymorphism probes that flanked in the miRNA genomic
regions were identified. CNV of the miRNAs were obtained
by averaging the logR ratio from those corresponding single-
nucleotide polymorphism probes. The same procedure was
used to study the CNV of all the 220 miRNAs. In addition to
analysis of the continuous CNV data, a hiddenMarkovmodel
(HMM) was applied to determine if there was copy number
gain or loss as described previously (Liu et al., 2009).
Results
Genomic amplification and deletion of miRNAs
We analyzed the miRNA expression levels in 94 pairs of
HCC tissues and corresponding adjacent nontumor tissues. A
subset of miRNAs was differentially expressed. Given the
changes in miRNA expression in HCC, it is important to un-
derstand how these changes occur. We first tested if the
changes in miRNA expression are due to genomic amplifi-
cation or deletion. We analyzed the SNP data from the same
set of samples, and determined whether the expression of the
miRNAs was associated with DNA copy number. We found
that nine differentially expressed miRNAs were significantly
correlated with DNA copy number with p-value< 0.05 after
Bonferroni correction and were amplified or deleted in ge-
nomes of tumor samples (Table 1). These miRNAs were
transcribed from seven distinct chromosomal loci. The geno-
mic loci contain two miRNA clusters, including miR-30e-3p
and miR-30c located at 1q34.2, also miR-18a and miR-19a lo-
cated at 13q31.3. We found that miR-30d and miR-151, both
located at chromosome 8, have high correlation with DNA
copy number (r¼ 0.6 and 0.7, respectively; Pearson correla-
tion, and p< 0.0001). These two miRNAs were significantly
overexpressed in HCC patients, and the genomic regions of
these two miRNAs were amplified in*50% of HCC patients
( p< 0.0005). Thus, the comparison of CNV with expression
data suggests that genomic alteration is one of the mecha-
nisms that contribute to the miRNA deregulation.
Changes in miRNA biosynthesis may contribute
to deregulation of miRNA expression
Recent studies suggested that proteins involved in miRNA
biosynthesis are deregulated in cancer, such as lung cancer
(Karube et al., 2005) and ovarian cancer (Merritt et al., 2008).
Therefore, we tested whether genes required for miRNA
biosynthesis were differentially expressed in our HCC tissue
samples. The expression level of genes DROSHA, DGCR8,
Table 1. Correlation of miRNA expression and DNA copy number (miRNAs Indicated
in Red Are Transcribed from Multiple Loci)
miRNA
Correlation
with DNA copy number p-value
Deletion
rate p-value
Amplification
rate p-value
miRNA Alteration
(frequency, %)
Chromosome 1
miR-34A 0.3823 0.0002 0.4205 <0.0001 — — Up (65.6)
miR-30E-3P 0.5336 <0.0001 0.2500 0.0450 — — Down (81.3)
miR-30C 0.4620 <0.0001 0.2500 0.0450 — — Down (74.0)
Chromosome 8
miR-30D 0.6111 <0.0001 — — 0.5568 0.0004 Up (76.0)
miR-151 0.7068 <0.0001 — — 0.5227 0.0004 Up (92.7)
Chromosome 13
miR-18A 0.4009 0.0001 0.2614 0.0331 — — Up (92.7)
miR-19A 0.5046 <0.0001 0.2614 0.0331 — — Up (67.7)
Chromosome 14
miR-345 0.4488 <0.0001 0.2841 0.0210 — — Up (75.0)
Chromosome 17
miR-21 0.3732 0.0003 — — 0.2841 0.0138 Up (90.6)
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DICER1, AGO1, AGO2, AGO3, and AGO4 were analyzed.
We found that DROSHA, DGCR8, AGO1, and AGO2, were
significantly overexpressed, whereas DICER1 and AGO3
were significantly downregulated in HCC tumor tissues than
in adjacent nontumor tissues (Fig. 1a). In addition, the ex-
pression levels of these genes were more variable in HCC
tumor tissues. Among the genes required for biosynthesis of
miRNAs, DROSHA was the most differentially expressed. It
is responsible for producing pre-miRNAs and thus may affect
the miRNA expression levels. We looked for miRNAs that are
positively correlated with DROSHA expression, and found
that seven miRNAs (miR-324-5p, -301, -222, -106a, -18a, -93,
and -106b) are positively correlated with DROSHA (Pearson
correlation >0.3 and p-value< 0.05 after Bonferroni correc-
tion) (Fig. 1b). The result suggests that changes in expression
of genes involved inmiRNAbiosynthesis may have an impact
on the expression levels of miRNAs in HCC.
Discussion
We found that the distinct miRNA signature of HCC tumor
is at least in part attributed to the frequent CNV (either gain
or loss) in cancer genomes. We showed that expression levels
of several miRNAs are highly correlated with either amplifi-
cation or deletion of the chromosomal regions from where
they are encoded. For example, the genomic regions of miR-
30d and miR-151 were amplified significantly in 56 and 52%,
respectively, in our clinical cohorts. A recent study reported
that the genomic region of miR-151 is frequently amplified in
HCC (Ding et al., 2010), which is in accordance with our re-
sults in this report. In addition, miR-21, which is often found
overexpressed in various types of cancer, is in a genomic re-
gion amplified in 28% of our clinical cohorts. It has been
shown that in chronic lymphocytic leukemia (CLL), CNV
influences expression of miRNAs. The genomic region en-
coding miR-15 and miR-16 is deleted in more than 50% of the
patients with CLL (Calin et al., 2002), and these miRNAs have
been shown to have tumor suppressing activities in a leuke-
mic xenograft model (Calin et al., 2008). It should be note that
the genomic region of miR-34a was deleted at a high rate of
42% in our patient cohort; however, it was overexpressed in
*65% of the tumor samples. Recent studies have reported the
inhibitory effect of miR-34a on tumor growth (Hermeking,
2007; Wiggins et al., 2010). Tumors with lower miR-34a ex-
pression due to genomic deletionmight havemore aggressive
phenotype. This subset of tumors is worthy of further inves-
tigation to enhance our understanding of the CNV action on
oncogenesis. CNV has been widely known to shape the
FIG. 1. Genes required for miRNA biosynthesis are differentially expressed between tumor and nontumor tissues. (a)
Scatter plots of log10 intensity of DICER1, DGCR8, AGO1, AGO2, AGO3, and DROSHA between tumor (TU) and adjacent
nontumor (AN) tissues. Differential expression was assessed by Student t-test. (b) Shown are the expression levels of the
seven miRNAs positively correlated with DROSHA expression in tumor and adjacent nontumor tissues from 94 patients. Left
panel: the blue dots indicate whether the tissue is tumor (Yes) or adjacent nontumor (No). Center panel: a heat map showing
the log10 ratio of expression level of each individual tissue sample to the mean of all tissue samples. Right panel: normalized
DROSHA intensity.
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transcriptome with its direct effect on gene expression
(Cooper et al., 2008). We herein suggested that CNV also in-
fluences HCC transcriptome through indirect or secondary
action via miRNAs.
In addition to the CNV causal effects, miRNA expression in
HCC is also affected by deregulated biogenesis. This kind of
deregulation has been observed in several types of solid
cancers including lung (Muralidhar et al., 2007), ovarian
(Flavin et al., 2008), cervical carcinomas (Muralidhar et al.,
2007), and breast cancer (Grelier et al., 2009), but remains
unknown in HCC. In our study, we found DROSHA was
significantly overexpressed in HCC tumor tissues. The over-
expression of DROSHA has also been reported in ovar-
ian (Flavin et al., 2008) and cervical carcinomas (Muralidhar
et al., 2007). We found seven miRNAs highly correlated
with DROSHA expression. Several of these miRNAs have
been reported to have oncogenic properties. For example,
miR-106b and miR-93 were overexpressed in HCC tumor
tissues and have a role in cell proliferation and anchorage-
independent growth (Li et al., 2009). On the other hand, the
downregulation of DICER1 expression was observed in our
clinical cohort. In lung cancer, the lower expression of
DICER1 promoted tumorigenesis in vitro and inmousemodel
(Kumar et al., 2007), whereas in ovarian cancer, low DICER1
expression was linked to poor overall survival (Faggad et al.,
2010). Together, the data show that key components of the
miRNA biosynthetic pathway emerge to play important roles
in cancer development.
Changes in miRNA expression were complex. By investi-
gating the SNP andmRNA data, we suggested that the CNV,
and changes in the expression of miRNA biosynthetic path-
way components may have pivotal role of contributing to the
aberrant expression of miRNAs in HCC. This study may
provide hints to further research on the molecular basis for
understanding changes in miRNA expression in the devel-
opment of HCC.
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